Barrett & Company’s Intellia Therapeutics NTLA Stock Holding History

Barrett & Company’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.85K	Hold	300	–	–	﹤0.01%	543
2025 Q4	$2.7K	Hold	300	–	–	﹤0.01%	568
2025 Q3	$5.18K	Hold	300	–	–	﹤0.01%	522
2025 Q2	$2.81K	Hold	300	–	–	﹤0.01%	565
2025 Q1	$2.13K	Hold	300	–	–	﹤0.01%	552
2024 Q4	$3.5K	Hold	300	–	–	﹤0.01%	525
2024 Q3	$6.17K	Hold	300	–	–	﹤0.01%	465
2024 Q2	$6.71K	Hold	300	–	–	﹤0.01%	465
2024 Q1	$8.25K	Hold	300	–	–	﹤0.01%	444
2023 Q4	$9.15K	Hold	300	–	–	0.01%	418
2023 Q3	$9.49K	Hold	300	–	–	0.01%	424
2023 Q2	$12.2K	Hold	300	–	–	0.01%	395
2023 Q1	$11.2K	Hold	300	–	–	0.01%	377
2022 Q4	$10.5K	Hold	300	–	–	0.01%	377
2022 Q3	$10.5K	Buy	+300	New	+$18.6K	0.01%	377

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barrett & Company's NTLA Position: Q1 2026 in Review

Barrett & Company held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 300 shares worth $3.85K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Barrett & Company first reported a position in NTLA in Q3 2022 and has held it in 15 quarters since. The position peaked at $12.2K in Q2 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Barrett & Company held 300 shares of Intellia Therapeutics worth $3.85K as of Q1 2026.
Barrett & Company left its Intellia Therapeutics share count unchanged in Q1 2026.
Intellia Therapeutics made up ﹤0.01% of Barrett & Company's portfolio in Q1 2026, its #543 holding.
Barrett & Company first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 15 quarters since.
Barrett & Company's Intellia Therapeutics position peaked at $12.2K in Q2 2023.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.